In 2005, Advances Made in Breast Cancer Treatment and Detection

	Tweet

It was a good year in women’s health, notably breast cancer treatment and detection. The December issue of Mayo Clinic Women’s HealthSource hails these important advances of 2005.

Breast cancer treatment

The results of several clinical trials established the value of two types of breast cancer drugs in preventing breast cancer recurrence, significantly improving disease-free survival rates.

In two large clinical trials, trastuzumab (Herceptin), which has been available for women with advanced breast cancer, was found to help women with early-stage HER-2 positive breast cancer—an aggressive form of the disease that tends to respond poorly to hormone treatment.

Women with early-stage HER-2 positive breast cancer who received Herceptin in combination with standard chemotherapy treatment had a 52 percent decrease in breast cancer recurrence when compared with women receiving chemotherapy alone.

Other studies published this year showed aromatase inhibitors (AIs) are an effective hormone treatment for postmenopausal women with hormone-positive early-stage breast cancer.

That’s significant because for at least two decades, the drug tamoxifen has been the gold standard add-on therapy used after initial treatment. Recent clinical trials have shown that AIs, which block an enzyme responsible for producing small amounts of estrogen in postmenopausal women, often show better disease-free survival rates than does tamoxifen alone or when used after several years of tamoxifen or as a first-line therapy for early-stage breast cancer.

Breast cancer detection
Several recent studies have shown that MRI –-- which uses magnetic energy and intravenous material to create detailed images of the breast—is significantly more sensitive than mammography in detecting breast cancers in high-risk women.

Researchers of a recent study concluded that combining MRI with mammography would pick up twice as many breast cancers in women at high risk. This advance is especially important for women with mutations on genes BRCA1 or BRCA2. They are typically at greater risk of developing breast cancer in their younger years, when dense breast tissue can make mammography X-rays difficult to interpret. 

RELATED STORIES:
Breast Cancer Experts Available for Comment   Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers   Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads   Ethnic breast cancer gap tied to mammography rates   Drug Combo Shrinks Breast Cancer Metastases in Brain   Minorities less likely to know about breast cancer options   Air Pollution Exposure Affects Chances of Developing Premenopausal Breast Cancer   Breast cancer surgery decisions difficult for many   Mammograms May Detect Some Cancers That Would Have Regressed   Breast cancer patients with BRCA gene diagnosed almost 8 years earlier than generation before   Physicians validate reclassification of breast cancer stages   Prenatal exposure to endocrine-disrupting chemicals linked to breast cancer   Vitamin D May Help Curb Breast Cancer Progression   Common transplant drug inhibits breast cancer growth, UNC laboratory study shows   Benefit of novel drug in breast cancer seen in blood within weeks   Chest X-rays may raise breast cancer risk for some   Understanding the racial gap in breast ca survival   Marijuana Compound Shows Promise in Fighting Breast Cancer   FISH Technology Preferred for Choosing HER-2-Positive Breast Cancer Treatments   Another step toward resisting breast cancer   Peaches, plums induce deliciously promising death of breast cancer cells   Exercise boosts well-being after breast cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]